CLVS stock forecast
Our latest prediction for Clovis Oncology, Inc.'s stock price was made on the Aug. 16, 2019 when the stock price was at 5.60$.
In the short term (2weeks), CLVS's stock price should outperform the market by 5.32%. During that period the price should oscillate between -9.72% and +21.19%.
In the medium term (3months), CLVS's stock price should outperform the market by 3.44%. During that period the price should oscillate between -21.60% and +42.54%.Get email alerts
About Clovis Oncology, Inc.
Clovis Oncology, Inc. is a commercial stage biotechnology company, which engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets. Its product development programs target specific subsets of cancer, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from its use. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
At the moment the company generates 119M USD in revenues.
On its last earning announcement, the company reported a loss of -7.50$ per share.
The book value per share is 5.93$
Three months stock forecastAug. 16, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|